C2I2.org
 Index to all volumes
  2008
  2007
  2006
  2005
  2004
  2003
 Useful web site addresses
 Contacting C2I2

Search for:
Type a word or a phrase. All forms of the word are searchable.

Click here to register to get free access to the newest editions on-line

Supported by


Michael J Glasby is a consultant interventional radiologist at the Derby Royal Infirmary, UK, with special interests in vascular intervention and EVAR. He qualified from University College London Medical School in 1991. After initially training in surgery, he made the change to radiology. He studied radiology at the University Hospitals of Leicester, UK and spent an additional 2 years working under Dr. Bolia – who pioneered subintimal angioplasty – at the Leicester Royal Infirmary.
Subintimal angioplasty

Michael J. Glasby,1 George Markose2 and Amman Bolia2
1Derby Royal Infirmary, London Road, Derby, UK
2Leicester Royal Infirmary, Infirmary Square, Leicester, UK

Address for correspondence:
Dr. Michael J. Glasby MBBS BSc MRCS FRCR
X-ray Department, Derby Royal Infirmary
London Road, Derby DE1 2QY, UK
Tel: +44 (0)1332-340131
Email: mike.glasby@derbyhospitals.nhs.uk

Abstract
The technique of subintimal angioplasty (SIA) has been in use for approximately two decades and is a suitable alternative to bypass surgery. It was originally described in the femoro-popliteal arteries but its scope has been extended to occluded vessels throughout the body from crural vessels to visceral arteries. SIA is a straightforward and easy technique to master but there is a learning curve. The procedure is well tolerated with a low complication rate and is comparable to conventional angioplasty. Initial technical success rates are high (74–92%). Reported long-term patency rates are variable but assisted patency rates can be as high as 64% at 5 years. In cases where SIA has failed, repeated studies show that it does not jeopardise future surgery. The procedure of SIA is still evolving: recent developments include devices to aid re-entry back to the true lumen and stent technology to assist long-term patency rates.